Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

FDA clears Mesoblast IND for remestemcel-L in ARDS caused by COVID-19

Mesoblast (NASDAQ:MESO; ASX:MSB) received clearance from the FDA for an IND application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with intravenous infusions of its allogeneic...

April 6, 2020

Developments

IntelGenx adjusts VersaFilm business strategy

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) unveiled a series of initiatives aimed at helping the company address, and satisfactorily respond to, the complete response letter that it recently received from the FDA...

April 6, 2020

Developments

Profound Medical launches TULSA patient website in U.S.

Profound Medical (NASDAQ:PROF; TSX:PRN) launched a newly designed TULSA Procedure website, for residents of the U.S. suffering from a prostate condition. “This new site aims to be credible and focused on providing clear...

April 3, 2020

Developments

Ennaid Therapeutics developing antiviral for COVID-19

Closely held Ennaid Therapeutics is advancing development of ENU200 as a therapeutic to treat the up to 80% of asymptomatic, mild-to-moderate cases of COVID-19 viral infections. ENU200 is a repurposed, patent-pending...

April 2, 2020

Developments

FDA accepts Mesoblast BLA for RYONCIL; agrees to priority review

The FDA accepted for priority review Mesoblast’s (NASDAQ:MESO; ASX:MSB) biologics license application filing for RYONCIL, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft...

April 1, 2020

Developments

MEI Pharma gets FDA fast track designation for follicular lymphoma

MEI Pharma’s (NASDAQ:MEIP) ME-401 received FDA fast track designation for the treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. The company is...

March 31, 2020

Developments

Zucara Therapeutics in $21-million Series A funding led by Perceptive Xontogeny

Closely held Zucara Therapeutics closed a $21-million Series A financing led by the Perceptive Xontogeny Venture (PXV) Fund. Proceeds will be used for Phase 1 and Phase 2 clinical trials of ZT-01, Zucara’s first-in...

March 31, 2020

Developments

Kleo Pharma in COVID-19 research pact with Green Cross LabCell

Closely held Kleo Pharmaceuticals entered into a research collaboration with South Korea-based Green Cross LabCell, a pioneer in the next generation of allogeneic, or “off-the-shelf” natural killer cell...

March 31, 2020

Developments

Kasraeian Urology treats first Jacksonville patient with Profound’s TULSA-PRO

Dr. Ali Kasraeian of the renowned Kasraeian Urology in Jacksonville, FL, in partnership with Vituro Health, treated their first patient with Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO medical device for...

March 27, 2020

Developments

iBio supporting AzarGen’s development of plant-made rituximab

iBio (NYSE AMERICAN:IBIO) will manufacture and characterize additional supplies of plant-made rituximab for South Africa’s AzarGen, enabling preclinical studies to compare plant-made rituximab to the original molecule...

March 26, 2020

Developments

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Georgia’s renowned Busch Center is now offering Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO procedure to treat unhealthy prostate tissue. The technology, which was cleared by the FDA in August 2019, provides...

March 26, 2020

Developments

iBio begins immunization studies of COVID-19 vaccine candidates

iBio (NYSE AMERICAN:IBIO) commenced immunization studies for its SARS-CoV-2 virus-like particle (VLP) program, IBIO-200, at Texas A&M University System laboratories. The company used its plant-based FastPharming...

March 26, 2020

FDA clears Mesoblast IND for remestemcel-L in ARDS caused by COVID-19

IntelGenx adjusts VersaFilm business strategy

Profound Medical launches TULSA patient website in U.S.

Ennaid Therapeutics developing antiviral for COVID-19

FDA accepts Mesoblast BLA for RYONCIL; agrees to priority review

MEI Pharma gets FDA fast track designation for follicular lymphoma

Zucara Therapeutics in $21-million Series A funding led by Perceptive Xontogeny

Kleo Pharma in COVID-19 research pact with Green Cross LabCell

Kasraeian Urology treats first Jacksonville patient with Profound’s TULSA-PRO

iBio supporting AzarGen’s development of plant-made rituximab

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

iBio begins immunization studies of COVID-19 vaccine candidates

Follow Us

General

More